Payment overview · 2025
General Payments
$835.54
38 reported records · 15 companies
Healthcare provider profile · identity verified
Gervacio D Diaz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MODESTO, CA · NPI 1700835451
Verified facts
What the public records show
CMS Open Payments records show Gervacio D Diaz, M.D. received $835.54 in general payments during 2025 across 38 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Paxlovid, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $168.85 | 20.2% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $156.76 | 18.8% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.69 | 11.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.45 | 6.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.10 | 5.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.59 | 5.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.07 | 5.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $43.58 | 5.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.91 | 3.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.93 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.36 | 3.5% | 1 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $28.57 | 3.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.43 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.16 | 2.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.09 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $835.54 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $168.85 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $156.76 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.78 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $55.78 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $55.45 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.07 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.91 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $32.91 | 1 | 2025 |
Source payment records
|
|||||
| TAKHZYRO Normalized: takhzyro |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.46 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.36 | 1 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 160 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 36 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 46 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
36 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 834 | 255 |
| Amlodipine Besylate | Amlodipine Besylate | 753 | 210 |
| Losartan Potassium | Losartan Potassium | 561 | 160 |
| Metformin Hcl | Metformin Hcl | 480 | 164 |
| Lisinopril | Lisinopril | 454 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 413 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 373 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 314 | 102 |
| Quetiapine Fumarate | Quetiapine Fumarate | 311 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 83 |
| Furosemide | Furosemide | 247 | 74 |
| Gabapentin | Gabapentin | 230 | 68 |
| Simvastatin | Simvastatin | 222 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 63 |
| Omeprazole | Omeprazole | 204 | 68 |
| Montelukast Sodium | Montelukast Sodium | 194 | 63 |
| Carvedilol | Carvedilol | 189 | 55 |
| Tramadol Hcl | Tramadol Hcl | 188 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 55 |
| Potassium Chloride | Potassium Chloride | 172 | 54 |
| Alprazolam | Alprazolam | 166 | 27 |
| Jardiance | Empagliflozin | 160 | 46 |
| Glimepiride | Glimepiride | 132 | 37 |
| Sertraline Hcl | Sertraline Hcl | 126 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 116 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 17 |
| Famotidine | Famotidine | 95 | 32 |
| Mirtazapine | Mirtazapine | 94 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 31 |
| Ezetimibe | Ezetimibe | 90 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 16 |
| Azithromycin | Azithromycin | 88 | 68 |
| Alendronate Sodium | Alendronate Sodium | 87 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 24 |
| Eliquis | Apixaban | 86 | 25 |
| Terazosin Hcl | Terazosin Hcl | 86 | 26 |
| Telmisartan | Telmisartan | 80 | 23 |
| Benazepril Hcl | Benazepril Hcl | 79 | 23 |
| Atenolol | Atenolol | 75 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 24 |
| Donepezil Hcl | Donepezil Hcl | 69 | 21 |
| Fenofibrate | Fenofibrate | 69 | 23 |
| Lovastatin | Lovastatin | 68 | 20 |
| Nifedipine Er | Nifedipine | 65 | 18 |
| Irbesartan | Irbesartan | 64 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 13 |
| Clonazepam | Clonazepam | 62 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 19 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 61 | suppressed |
| Lorazepam | Lorazepam | 59 | 12 |
| Valsartan | Valsartan | 56 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 18 |
| Ozempic | Semaglutide | 54 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 15 |
| Finasteride | Finasteride | 52 | 15 |
| Meloxicam | Meloxicam | 52 | 20 |
| Trazodone Hcl | Trazodone Hcl | 51 | 17 |
| Amoxicillin | Amoxicillin | 47 | 41 |
| Morphine Sulfate Er | Morphine Sulfate | 46 | suppressed |
| Ibuprofen | Ibuprofen | 45 | 13 |
| Prednisone | Prednisone | 45 | 33 |
| Xarelto | Rivaroxaban | 45 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 12 |
| Glipizide | Glipizide | 44 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 12 |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 19 |
| Farxiga | Dapagliflozin Propanediol | 41 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | 13 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 30 |
| Dutasteride | Dutasteride | 36 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 35 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Estradiol | Estradiol | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 14 |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | 11 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Benzonatate | Benzonatate | 14 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Nystatin | Nystatin | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $835.54 · 38 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, BREZTRI, CAPLYTA, COMIRNATY, CONTRAVE, EVENITY, GEMTESA, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, ORLADEYO, OTEZLA, PAXLOVID, PREVNAR 20, PROLIA, REPATHA, REXULTI, TAKHZYRO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error